Schwab Network on $HIMS (Nov 18, 2026)
HIMS launched Peptides Plus with five combination therapies, which could draw new customers beyond traditional telehealth and add recurring revenue amid rising peptide demand, but none of the initial treatments is FDA-approved and HIMS says safety, effectiveness and dosing are still uncertain; regulatory and scientific risk could materially threaten its growth plans.
Playing via YouTube may share device and playback data and use cookies. Privacy Notice · Google Privacy Policy
Jump to any passage
Hims&Hers may have missed out on the " hot peptide summer," but there may be a " hot peptide winter" coming, as it launches its new "Peptides Plus" platform offering five combination therapies targeting everything from energy and recovery to cellular health.
This move comes at a time when demand for peptides is increasing, but there is a major obstacle here . None of the initial treatments are approved by the Food and Drug Administration (FDA), and the company itself acknowledges that there is still much to learn about their safety, effectiveness, and appropriate dosages .
For Hims, the opportunity to tap into this potentially huge new market could attract new customers looking beyond traditional telehealth offerings , and could also give them the chance to build another recurring income stream.
But investors will also be watching the regulatory landscape closely, because the scientific uncertainty fueling skepticism about peptides could ultimately become a major risk to the company's growth ambitions.
What this channel has said about $HIMS
Schwab Network has 3 calls on this stock; only the adjacent ones are shown.